Population Pharmacokinetics of Ganciclovir in Critically Ill Patients.

08:00 EDT 16th August 2019 | BioPortfolio

Summary of "Population Pharmacokinetics of Ganciclovir in Critically Ill Patients."

The pharmacokinetic (PK) data of ganciclovir (GCV), a first-line antiviral treatment for cytomegalovirus infections, in critically ill patients is limited. This study aimed at characterizing GCV population PK and inter-individual variability (IIV) in ICU patients. Secondary objectives were to identify patient characteristics responsible for IIV and simulate GCV exposure for different dosing regimens.


Journal Details

This article was published in the following journal.

Name: Therapeutic drug monitoring
ISSN: 1536-3694


DeepDyve research library

PubMed Articles [31639 Associated PubMed Articles listed on BioPortfolio]

Paediatric ganciclovir dosing in extracorporeal membrane oxygenation: Is standard dosing good enough?

Ganciclovir is a first-line antiviral agent to treat cytomegalovirus disease in immunocomprimised patients. Ganciclovir pharmacokinetics in ECMO is unknown.

Population Pharmacokinetics of Vancomycin under Continuous Renal Replacement Therapy using a Polymethylmethacrylate Hemofilter.

Although continuous hemodiafiltration (CHDF) is often performed in critically ill patients during sepsis treatment, the pharmacokinetics of vancomycin (VCM) during CHDF with a polymethylmethacrylate h...

Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.

Sustained low-efficiency dialysis (SLED) is a hybrid form of dialysis that is increasingly used in critically ill patients with kidney injury and hemodynamic instability. Antimicrobial dosing for pati...

Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.

To evaluate extended-infusion cefepime pharmacokinetics (PK) and pharmacodynamic (PD) target attainment in critically ill patients receiving continuous venovenous hemofiltration (CVVH) or continuous v...

Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors.

Critically ill patients are exposed to a high risk of developing thromboembolism. Moreover, standard prophylaxis with subcutaneous (SC) heparin is less efficient in patients requiring vasopressors. Th...

Clinical Trials [9030 Associated Clinical Trials listed on BioPortfolio]

Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy

In order to optimize anti-cytomegalovirus (CMV) treatment with ganciclovir (GCV), in patients with multi organ failure treated with continuous renal replacement therapy (RRT), more informa...

An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children

To evaluate the pharmacokinetics of intravenous ganciclovir in children (ages 3 months - 12 years). To determine the safety and tolerance of a 2 to 3 week induction course of ganciclovir I...

Nomograms for Optimization of Amikacin First Dose in Critically Ill Patients Using a Population Pharmacokinetics Model

The aim of this study is to elaborate nomograms to optimize amikacine first dosing in critically ill patients, using a population pharmacokinetics model elaborated with multicentric data.

(Val)Ganciclovir TDM in Transplant Recipients

The aim of this study is to gain more insight into therapeutic drug monitoring and thus the pharmacodynamics and pharmacokinetics of ganciclovir, in the context of prophylaxis and treatmen...

A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir

To determine the pharmacokinetics (blood levels) of three dose treatment plans of oral ganciclovir during a 28-day dosing period. Other purposes of the study are to determine in a populati...

Medical and Biotech [MESH] Definitions

An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

A hematopoietic growth factor which promotes proliferation and maturation of neutrophil granulocytes. Clinically it is effective in decreasing the incidence of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive therapy or in reducing the duration of neutropenia and neutropenia-related clinical sequelae in patients with non-myeloid malignancies undergoing myeloblastive chemotherapy followed by BMT. It has also been used in AIDS patients with CMV retinitis being treated with GANCICLOVIR. (Gelman CR, Rumack BH & Hess AJ (eds): DRUGDEX(R) System. MICROMEDEX, Inc., Englewood, Colorado (Edition expires 11/30/95))

Ongoing scrutiny of a population (general population, study population, target population, etc.), generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than by complete accuracy.

Registered nurses with graduate degrees in nursing who provide care to pediatric patients who are acutely or critically ill.

A nursing specialty that deals specifically with the care of patients who are critically ill.

Quick Search

DeepDyve research library

Searches Linking to this Article